Surgical Menopause New Zealand Trust

When both ovaries are removed during surgery, women instantly lose around 50% of their testosterone – a hormone that plays a key role in sexual function, energy, and overall wellbeing.

AndroFeme, the only testosterone treatment specifically formulated and approved for women, remains unfunded in New Zealand. Many women cannot afford it, and others are left using Testogel, a male product prescribed off-label, which carries a higher risk of overdosing and has limited safety data for women.

Can you imagine a man being told he’ll lose half his testosterone overnight and must pay out of pocket to replace it? This has been the reality for countless women after surgical menopause.

Women in New Zealand deserve equitable access to safe, evidence-based treatment at every stage of life, including menopause. While four testosterone products are fully funded for men, AndroFeme – the only formulation specifically designed and approved for women – remains unfunded, putting effective treatment out of reach for many.

AndroFeme is approved for Hypoactive Sexual Desire Disorder (HSDD), a distressing loss of libido that can affect wellbeing, relationships, and confidence. Funding AndroFeme would provide women with a safe, effective, and evidence-based treatment option – something men already have.

You can make a difference. Support women’s health by signing the petition to fund AndroFeme in New Zealand: visit: https://www.change.org/p/pharmac-fund-androfeme-the-only-approved-testosterone-treatment-for-women-in-nz.